CyclomicsSeq: targeted and genome-wide detection of circulating tumor DNA using nanopore consensus sequencing
- Published on: April 6 2022
Wigard Kloosterman, Cyclomics, demonstrated how CyclomicsSeq can facilitate the detection of mutations with a frequency of at least 0.02% in cfDNA in blood. He also discussed its potential for minimally-invasive presymptomatic screening in the future.
